MedTrace Logo

A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial

NCT04927936 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 432

Last updated 2021-06-30

No results posted yet for this study

Summary

The key objective of the study is to measure the immune response against SARS-CoV-2 after different vaccinations in Health Care Workers (HCW) from 18 to 65 years old vaccinated once with Janssen vaccine.

Determination of antibodies by a quantitative immunoglobulin G (IgG) assay (LIAISON SARS-CoV-2 TRIMERICS IgG essay) 28 days after second vaccination (booster) comparing, per protocol, the following three groups:

1. Janssen vaccine/- vs. Janssen vaccine/Janssen vaccine
2. Janssen vaccine/Janssen vaccine vs. Janssen vaccine/Pfizer vaccine
3. Janssen vaccine/Janssen vaccine vs. Janssen vaccine/Moderna vaccine

Conditions

  • Covid19

Interventions

BIOLOGICAL

Vaccination once with Janssen vaccine (only priming)

Vaccination (priming) with janssen vaccine. There is no boosting.

BIOLOGICAL

Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).

Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.

BIOLOGICAL

Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).

Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.

BIOLOGICAL

Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).

Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.

Sponsors & Collaborators

  • Leiden University Medical Center

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • Hugo van der Kuy, PhD, PharmD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-25
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04927936 on ClinicalTrials.gov